MHRA expands Safety Public Assessment Reports with new medicine safety reviews
The MHRA has added several new Safety Public Assessment Reports to its national medicines safety archive, extending a long-running record of regulatory decisions on medicines and drug classes. The latest additions span antidepressants, bladder anticholinergics, gabapentinoids, benzodiazepines, Z-drugs, isotretinoin, fluoroquinolone antibiotics, modified-release opioids, and valproate. For clinicians, the page functions less like a treatment guide and more like a regulatory ledger: it captures the evidence that was available when a safety decision was made and preserves the logic behind the action.
The timing of those additions matters in practice because medicines safety rarely hinges on a single study. Regulators usually respond to a pattern — case reports, observational signals, epidemiology, pharmacovigilance reviews, and the biological plausibility of harm. When a drug class reaches the level of a national assessment report, the concern is often no longer theoretical. The question becomes how to reduce avoidable harm without stripping patients of a medicine that still has legitimate therapeutic value.
A regulatory archive built around national safety decisions
The MHRA describes Safety Public Assessment Reports as reports that explain the scientific evidence used to lead regulatory decisions on the safety of medicines or medicine classes. The reports are prioritised when they relate to major national regulatory action. They also serve a narrow, specific purpose: they are not intended to provide clinical advice, but to show the evidence base that sat behind a decision at the time it was made.
That framework gives the reports unusual value for prescribers, pharmacists, and policy teams. A PAR does not simply state that a product carries a risk. It records why the risk was judged important enough to trigger regulatory attention, what evidence was available, and how the conclusion fit into the broader safety picture. For medicines with well-known adverse-effect profiles, those documents often become the historical trail for changes in labelling, prescribing advice, restrictions, or patient-information materials.
Since 2012, most safety issues have been assessed at an EU level, with reports now hosted by the European Medicines Agency or the Head of Medicines Agency websites. The MHRA page still points readers toward monthly Drug Safety Update notices and toward standard Public Assessment Reports as separate resources. The result is a layered system: national regulatory decisions, European-level assessment for many issues, and continuing prescribing updates for frontline use.
2026 additions place neuropsychiatric and long-term safety in focus
The most recent update, dated 15 October 2026, added a PAR on antidepressants with updated safety communications. On 27 July 2026, the page gained a report on bladder anticholinergics and risk of dementia. Earlier in 2026, the MHRA also added reports addressing gabapentinoids, benzodiazepines, and Z-drugs, along with a review of the impact of recommendations for prescribing isotretinoin.
These drug classes sit at the intersection of symptom control and safety risk. Antidepressants and sedative-hypnotics are widely used, often for chronic conditions, and the adverse effects that prompt regulatory review may emerge only after prolonged exposure or in vulnerable populations. Bladder anticholinergics are particularly relevant because anticholinergic burden can accumulate across prescriptions, raising concern about central nervous system effects in older adults. Isotretinoin carries a separate, long-recognised need for careful risk management because of its use in acne and the consequences of pregnancy exposure.
A single medication can become a public-health question when exposure is broad enough.
2025 reports sharpen attention on reproductive, postoperative, and antibiotic risk
The 2025 entries on the page widen the safety lens further. The MHRA added a report on fluoroquinolone antibiotics and risk minimisation for disabling and potentially long-lasting or irreversible side effects. It also added a PAR on modified release opioids and treatment of postoperative pain, alongside a report on valproate and reproductive risks in male patients under 55.
Each of those topics reflects a different regulatory problem. Fluoroquinolones have long been associated with serious adverse reactions that can outlast the treatment course itself, making risk minimisation central to their use. Modified-release opioids in postoperative pain raise the practical issue of matching formulation to indication, because prolonged opioid exposure after surgery can create dependence and other harms without clear added benefit if short-acting options would suffice. Valproate remains one of the clearest examples of a medicine whose benefits in seizure and mood control must be weighed against reproductive risk signals that extend beyond the treated patient.
The biological logic behind those reviews is not obscure. Medicines that alter connective tissue, the nervous system, or embryonic development demand a lower tolerance for preventable exposure, especially when alternative treatments exist. Regulatory action in those settings is often a recognition that harm can be predictable enough to justify tighter prescribing boundaries rather than broader use.
Earlier reports show how safety concerns migrate from signal to policy
The archive also lists major reports from prior years on topics including hydroxychloroquine or chloroquine in combination with macrolide antibiotics, chloramphenicol eye drops in young children, haloperidol for acute delirium in older patients, macrolide antibiotics in pregnancy, antiepileptic drugs in pregnancy, over-the-counter stimulant laxatives, yellow fever vaccine, oral lidocaine products used in teething, pseudoephedrine and ephedrine misuse, isotretinoin and psychiatric adverse reactions, aqueous cream and skin reactions, HPV vaccines, fluoxetine in pregnancy, tamoxifen interactions with CYP2D6 inhibitors, nicotine replacement therapy, NSAID cardiovascular risk, warfarin safety information, and finasteride risk.
Read as a group, these reports show a familiar regulatory pattern. A concern appears first as a signal, then becomes an evidence review, then reaches the level of a prescribing recommendation, restriction, withdrawal, or safety communication. Some of the issues are acute and obvious, such as paediatric misuse risk or cardiovascular toxicity. Others are slower and harder to detect, including psychiatric effects, fetal exposure concerns, or cumulative vascular harm from chronic anti-inflammatory use.
Those pathways matter because safety regulation in medicine is rarely about banning entire therapeutic classes. It is about narrowing exposure to the patients who stand to benefit most, while keeping the risk within bounds that clinicians can justify at the bedside. A pregnant patient, an older adult with delirium, a child receiving a topical or oral medicine, or a postoperative patient sent home with opioids each sits in a different risk environment. The regulatory response has to reflect that variation.
What the archive makes possible for prescribers and patients
The page itself does not give prescribing advice, and it is not designed to replace clinical judgment. Its value lies in transparency. Clinicians can trace how the MHRA evaluated evidence at a given moment, compare reports across drug classes, and understand why some concerns were escalated while others were managed through communication and monitoring.
For patients, the existence of the archive is a reminder that medicine safety is not static. A drug can remain useful while its acceptable conditions of use become narrower. A class can stay on the market while regulators strengthen warnings, refine indications, or call attention to a specific high-risk subgroup.
The central limitation is built into the format: these reports are a snapshot of evidence at the time of regulatory action, not a full substitute for current prescribing information. The next question is not whether the archive will keep growing — it will — but which signals will be strong enough to trigger the next national review, and which will remain at the level of routine surveillance.